NO992196L - Notch - Google Patents

Notch

Info

Publication number
NO992196L
NO992196L NO992196A NO992196A NO992196L NO 992196 L NO992196 L NO 992196L NO 992196 A NO992196 A NO 992196A NO 992196 A NO992196 A NO 992196A NO 992196 L NO992196 L NO 992196L
Authority
NO
Norway
Prior art keywords
compounds
cell
interactions
relates
notch
Prior art date
Application number
NO992196A
Other languages
English (en)
Other versions
NO992196D0 (no
Inventor
Jonathan Robert Lamb
Margaret Jane Dallman
Gerard Francis Hoyne
Original Assignee
Lorantis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9623236.8A external-priority patent/GB9623236D0/en
Priority claimed from GBGB9715674.9A external-priority patent/GB9715674D0/en
Priority claimed from GBGB9719350.2A external-priority patent/GB9719350D0/en
Application filed by Lorantis Ltd filed Critical Lorantis Ltd
Publication of NO992196D0 publication Critical patent/NO992196D0/no
Publication of NO992196L publication Critical patent/NO992196L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
NO992196A 1996-11-07 1999-05-05 Notch NO992196L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9623236.8A GB9623236D0 (en) 1996-11-07 1996-11-07 Notch
GBGB9715674.9A GB9715674D0 (en) 1997-07-24 1997-07-24 Notch
GBGB9719350.2A GB9719350D0 (en) 1997-09-11 1997-09-11 Notch
PCT/GB1997/003058 WO1998020142A1 (en) 1996-11-07 1997-11-06 Notch

Publications (2)

Publication Number Publication Date
NO992196D0 NO992196D0 (no) 1999-05-05
NO992196L true NO992196L (no) 1999-07-05

Family

ID=27268574

Family Applications (1)

Application Number Title Priority Date Filing Date
NO992196A NO992196L (no) 1996-11-07 1999-05-05 Notch

Country Status (20)

Country Link
EP (2) EP1616958A3 (no)
JP (1) JP4339406B2 (no)
KR (1) KR100393234B1 (no)
CN (2) CN1524583A (no)
AT (1) ATE299184T1 (no)
AU (1) AU736361B2 (no)
BG (1) BG103444A (no)
CA (1) CA2271248C (no)
CZ (1) CZ295997B6 (no)
DE (1) DE69733695T2 (no)
ES (1) ES2243986T3 (no)
GB (2) GB2353094B (no)
GE (1) GEP20043390B (no)
IL (1) IL129531A0 (no)
NO (1) NO992196L (no)
NZ (1) NZ335549A (no)
PL (1) PL333302A1 (no)
RO (1) RO120850B1 (no)
TR (1) TR199901000T2 (no)
WO (1) WO1998020142A1 (no)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU723939B2 (en) 1995-06-28 2000-09-07 Imperial Cancer Research Technology Ltd Nucleotide and protein sequences of vertebrate delta genes and methods based thereon
US5780300A (en) * 1995-09-29 1998-07-14 Yale University Manipulation of non-terminally differentiated cells using the notch pathway
GB9824045D0 (en) * 1998-11-03 1998-12-30 European Molecular Biology Lab Embl Regulator protein
GB9827604D0 (en) * 1998-12-15 1999-02-10 Lorantis Ltd Methods of immunosuppression
GB9927328D0 (en) * 1999-11-18 2000-01-12 Lorantis Ltd Immunotherapy
GB0019242D0 (en) * 2000-08-04 2000-09-27 Lorantis Ltd Assay
US6689744B2 (en) 2000-09-22 2004-02-10 Genentech, Inc. Notch receptor agonists and uses
JP4365583B2 (ja) 2000-09-22 2009-11-18 ジェネンテック・インコーポレーテッド ノッチレセプターアゴニスト及び用途
WO2003011317A1 (en) * 2001-07-25 2003-02-13 Lorantis Limited Modulators of notch signalling for use in immunotherapy
GB0118155D0 (en) * 2001-07-25 2001-09-19 Lorantis Ltd Superantigen
GB0123379D0 (en) * 2001-09-28 2001-11-21 Lorantis Ltd Modulators
US7682825B2 (en) * 2002-02-06 2010-03-23 Sanbio, Inc. Differentiation of bone marrow stromal cells to neural cells or skeletal muscle cells by introduction of notch gene
WO2003087159A2 (en) * 2002-04-05 2003-10-23 Lorantis Limited Modulators of the notch signalling pathway and uses thereof in medical treatment
JP2006513260A (ja) * 2002-08-03 2006-04-20 ロランティス リミテッド Ｎｏｔｃｈシグナル伝達経路調節因子の複合体およびその薬物治療への使用
GB0218879D0 (en) * 2002-08-14 2002-09-25 Lorantis Ltd Medical treatment
GB0220658D0 (en) * 2002-09-05 2002-10-16 Lorantis Ltd Immunotherapy
EP1549347A1 (en) * 2002-10-09 2005-07-06 Lorantis Limited Modulation of immune function
WO2004060262A2 (en) * 2003-01-07 2004-07-22 Lorantis Limited Modulators of notch signalling for use in immunotherpapy
GB0300428D0 (en) * 2003-01-09 2003-02-05 Lorantis Ltd Medical treatment
JP2006517533A (ja) * 2003-01-23 2006-07-27 ロランティス リミテッド Ｎｏｔｃｈシグナル伝達経路のアクチベーターを用いる自己免疫疾患の治療
GB0303663D0 (en) * 2003-02-18 2003-03-19 Lorantis Ltd Assays and medical treatments
ATE474593T1 (de) * 2003-03-21 2010-08-15 Celldex Therapeutics Ltd Behandlung von allergischen erkrankungen unter verwendung eines modulators des notch signaling pathway
WO2004083372A2 (en) * 2003-03-21 2004-09-30 Lorantis Limited Modulators of the notch signaling pathway immobilized on particles for modifying immune responses
GB0307472D0 (en) * 2003-04-01 2003-05-07 Lorantis Ltd Medical treatment
ES2413087T3 (es) 2006-06-13 2013-07-15 Oncomed Pharmaceuticals, Inc. Composiciones y métodos para el diagnóstico y tratamiento del cáncer
EP2125887A4 (en) 2007-01-24 2010-11-10 Oncomed Pharm Inc COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF CANCER
EP2899211A1 (en) 2008-07-08 2015-07-29 OncoMed Pharmaceuticals, Inc. Notch1 receptor binding agents and methods of use thereof
KR20110074846A (ko) * 2008-08-22 2011-07-04 더 트러스티스 오브 컬럼비아 유니버시티 인 더 시티 오브 뉴욕 노치３ 신호전달의 디코이 억제제로서의 인간 노치３ 기반 융합 단백질
EP2396021B1 (de) * 2009-02-16 2015-08-19 Miltenyi Biotec GmbH In vitro verwendung von notch-regulatoren zur modulation der immunantwort durch induktion/suppression von interleukin-22
JP5903382B2 (ja) 2009-08-29 2016-04-13 アッヴィ・インコーポレイテッド 治療用ｄｌｌ４結合タンパク質
CN105037543B (zh) 2010-03-02 2020-11-03 Abbvie 公司 治疗性dll4结合蛋白
CN103547275B (zh) * 2011-04-06 2016-12-28 桑比欧公司 用于调节外周免疫功能的方法和组合物
BR112014011925A2 (pt) * 2011-11-16 2017-05-30 Oncomed Pharm Inc mutações no receptor notch humano e seu uso
EP2846818A1 (en) * 2012-05-10 2015-03-18 Institut National de la Santé et de la Recherche Médicale (INSERM) Immunomodulatory methods using notch agonists
KR101573650B1 (ko) 2015-02-04 2015-12-01 성균관대학교산학협력단 Hcmv 바이러스 복제 억제용 조성물
SG11202101455TA (en) * 2018-08-28 2021-03-30 Hutchinson Fred Cancer Res Methods and compositions for adoptive t cell therapy incorporating induced notch signaling

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL101728A (en) * 1991-05-03 2007-08-19 Univ Yale Human Abandonment and Delta, Restrictive Areas of Effect in Tophoric Proteins, and Methods Based on Them
US5869282A (en) * 1991-12-11 1999-02-09 Imperial Cancer Research Technology, Ltd. Nucleotide and protein sequences of the serrate gene and methods based thereon
US5786158A (en) * 1992-04-30 1998-07-28 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
EP0742830B1 (en) * 1994-02-01 2001-07-18 THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services Fusion proteins that include antibody and nonantibody portions
US5780300A (en) * 1995-09-29 1998-07-14 Yale University Manipulation of non-terminally differentiated cells using the notch pathway
WO1997019172A1 (fr) * 1995-11-17 1997-05-29 Asahi Kasei Kogyo Kabushiki Kaisha Polypeptide suppresseur et de differenciation

Also Published As

Publication number Publication date
TR199901000T2 (xx) 1999-07-21
CZ295997B6 (cs) 2005-12-14
NZ335549A (en) 2001-07-27
BG103444A (en) 2000-06-30
CA2271248A1 (en) 1998-05-14
KR100393234B1 (ko) 2003-07-31
JP4339406B2 (ja) 2009-10-07
CN1524583A (zh) 2004-09-01
GB0023691D0 (en) 2000-11-08
DE69733695D1 (de) 2005-08-11
ES2243986T3 (es) 2005-12-01
GB2335194A (en) 1999-09-15
KR20000053146A (ko) 2000-08-25
EP0942998A1 (en) 1999-09-22
DE69733695T2 (de) 2006-05-18
GB9910276D0 (en) 1999-06-30
AU4876597A (en) 1998-05-29
CN1242802A (zh) 2000-01-26
GB2353094A (en) 2001-02-14
GB2353094B (en) 2001-06-13
JP2001504331A (ja) 2001-04-03
NO992196D0 (no) 1999-05-05
ATE299184T1 (de) 2005-07-15
GEP20043390B (en) 2003-11-10
EP0942998B1 (en) 2005-07-06
RO120850B1 (ro) 2006-08-30
EP1616958A3 (en) 2006-02-08
EP1616958A2 (en) 2006-01-18
IL129531A0 (en) 2000-02-29
GB2335194B (en) 2001-04-25
CN1160371C (zh) 2004-08-04
WO1998020142A1 (en) 1998-05-14
CZ163999A3 (cs) 1999-10-13
PL333302A1 (en) 1999-11-22
AU736361B2 (en) 2001-07-26
CA2271248C (en) 2009-08-11

Similar Documents

Publication Publication Date Title
NO992196D0 (no) Notch
ATE476495T1 (de) Bazillus thuringiensis und dessen insektizide proteine
DE69526856D1 (de) Nukleinsäure enthaltender impstoff
DE69733247D1 (de) Humanisiertes grünes-fluoreszenzprotein und methoden
DE69838986D1 (de) Polypeptide, deren herstellung und verwendung
DE69825625D1 (de) Aminobiguanide und ihre verwendung zur desinfektion von kontaktlinsen und konservierung von pharmazeutischen zubereitungen
DE69523654D1 (de) Verwendung von Ascorbyl-gamma-Linolenat und von Ascorbyl-dihomo-gamma-linolenat zur Behandlung von Asthma, Krebs, kardiovaskulären und inflammatorischen Erkrankungen
DE59610633D1 (de) Medikament, insbesondere zur modulation der immunantwort bei der bekämpfung von viren, tumoren, bakterien und parasiten
ATE364090T1 (de) Parapockenviren, die fremd-dna enthalten, ihre herstellung und ihre verwendung in impfstoffen
ATE295727T1 (de) Verwendung bestimmter substituierter pyrrolidone wie z.b. piracetam bei der behandlung von viralen und anderen erkrankungen
DE59811437D1 (de) Oxiranyl-triazolinthione und ihre verwendung als mikrobizide
ES2099678B1 (es) Procedimiento para la inactivacion de virus en proteinas.
DK0579939T3 (da) Phospholipidderivater
BR9407357A (pt) Novos tripeptideos utilizáveis em terapia cns e imune
EP0270841A3 (de) 2-Methyl-3-(p-methyl-phenyl)-propionitril, dessen Herstellung und Verwendung als Riechstoff
AU1318797A (en) Peptides and uses thereof for therapy of celiac diseases
NO964688L (no) Ny peptid-aktivsubstans og fremstilling av denne
AU6722498A (en) Disubstituted biphenyloxazolines
DE69733026D1 (de) Cyclin e spezifische konstrukte und komplexe
ATE30238T1 (de) N-acylderivate von peptiden, ihre herstellung und verwendung bei der bekaempfung von krankheiten und mittel dafuer.
NO982151D0 (no) Hemoregulatoriske forbindelser
DE69825307D1 (de) Verwendung von protein h als zytostattischer wirkstoff
UA9703A (uk) Антипротеіназний засіб